Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study.
OBJECTIVE
This single-arm, open-label study aimed to explore the effects of extended-release paliperidone on social and cognitive function in patients with schizophrenia.


METHODS
Paliperidone extended-release (flexible dose ranging from 3 to 12 mg/day orally) was administered for 24 weeks in patients with schizophrenia. Patient function was assessed using the personal and social performance scale, measurement and treatment research to improve cognition in schizophrenia initiative-consensus cognitive battery, positive and negative syndrome scale, and clinical global impression-severity.


RESULTS
Ninety patients were included in the full analysis set, while 72 patients were included in the per protocol set. The personal and social performance score was 54.3±14.3 at baseline, and significantly increased to 73.4±12.6 at week 24 (P<0.001). For the measurement and treatment research to improve cognition in schizophrenia initiative-consensus cognitive battery assessment, six of the nine individual subtests, six of the seven cognitive domains, and total cognitive scores improved significantly (P<0.05) between baseline and endpoint. positive and negative syndrome scale total scores and clinical global impression-severity scores decreased gradually (P<0.001) from week 4 to the conclusion of the study.


CONCLUSIONS
Paliperidone extended-release treatment significantly improves social and neurocognitive function as well as symptoms in Chinese patients with schizophrenia.
Clinical Research Center, Peking University Sixth Hospital; Clinical Research Center, Peking University Institute of Mental Health; Key Laboratory of Mental Health, Ministry of Health (Peking University); National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing.
Chuan
C
Shi
Clinical Center of Psychology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province.
Shu Qiao
SQ
Yao
Department of Psychiatry, Institute of Mental Health, Shanghai Jiao Tong University, Shanghai.
Yi Feng
YF
Xu
Department of Psychiatry, Xi'an Mental Health Center, Xian, Shanxi Province.
Jian Guo
JG
Shi
Department of Psychiatry, The First Affiliated Hospital of Kunming Medical School, Kunming, Yunnan Province.
Xiu Feng
XF
Xu
Department of Psychiatry, The First Haerbin Psychiatric Hospital, Haerbin, Heilongjiang Province, People's Republic of China.
Cong Pei
CP
Zhang
Department of Psychiatry, University of California at San Diego, La Jolla, San Diego, CA, USA.
Hua
H
Jin
Clinical Research Center, Peking University Sixth Hospital; Clinical Research Center, Peking University Institute of Mental Health; Key Laboratory of Mental Health, Ministry of Health (Peking University); National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing.
Xin
X
Yu
neurocognition; paliperidone; schizophrenia; social function